Here is some information in relation to Daybue revenue that is worth considering despite the recent revenue down grade:
*Daybue revenue increased $8.7M[11.5%] in Q2 2024 compared to the previous quarter.
*Q2 2024 revenue is only just short of the previous unusually high Q4 2023 result which was said to involve on-off seasonal factors.
*Daybue sales so far this calendar year total $160M.Daybue sales only have to generate about another $90M this calendar year to achieve a milestone payment of $50M for sales in excess of $250M in one calendar year.This is about 4 times the last quarters royalties payment.
*Daybue is also currently available in India via the Indian Pharma Network as indicated below:
"Indian Pharma Network helps in accessing new products in India.These products are launched and approved recently in USA or Europe but yet to be approved in India. We help in accessing these new launches through named patient import".
Kens
Acadia, page-847
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.11 |
Change
0.410(3.23%) |
Mkt cap ! $1.675B | |||
| Open | High | Low | Value | Volume |
| $13.02 | $13.12 | $12.89 | $8.524M | 654.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 5580 | $13.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.11 | 11667 | 1 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |